NIH Funding Opportunities (Notices, PA, RFA)

Subscribe to NIH Funding Opportunities (Notices, PA, RFA) feed
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 2 hours 12 min ago

Co-infection and Cancer (R21 Clinical Trial Not Allowed)

Thu, 2024-11-07 10:40
Funding Opportunity PAR-25-083 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection and cancer to shed light on presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents either concurrently or sequentially and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment.

Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed)

Thu, 2024-11-07 10:40
Funding Opportunity PAR-25-186 from the NIH Guide for Grants and Contracts. Through this funding opportunity announcement, the National Cancer Institute (NCI) solicits applications to Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts PAR. This funding opportunity announcement seeks to support initiating and building the next generation of population-based cancer epidemiology cohorts to address specific knowledge gaps in cancer etiology and survivorship. Specifically, it will support methodological work necessary to initiate and build cancer epidemiology cohorts that can address critical scientific gaps concerning (i) new or unique exposures in relation to cancer risks and outcomes and (ii) achievement of diverse populations in cohorts with the inclusion of understudied populations (e.g., racial/ethnic groups, rural populations, and persistent poverty areas) with substantial community engagement.

NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required)

Thu, 2024-11-07 01:33
Funding Opportunity PAR-25-049 from the NIH Guide for Grants and Contracts. This announcement (NOFO) encourages applications for multi-center clinical trials focused on neurological emergencies. Successful applicants will collaborate and conduct the trial within the NIH SIREN Network. The NIH SIREN Clinical Coordinating Center (CCC) will work with the successful applicants to implement the proposed trial efficiently and the SIREN Data Coordinating Center (DCC) will provide statistical and data management support. The NIH SIREN hubs and their affiliated clinical sites will provide on-site implementation of the clinical protocols. The NIH SIREN Network will also be uniquely poised to collaborate with other US and international consortia necessary to conduct larger, definitive trials of promising interventions for neurological emergencies. Multi-center clinical trials in stroke treatment, recovery, or prevention supported by NINDS will be conducted in the NIH StrokeNet, and not within SIREN. Applicants do not need to be part of the existing SIREN infrastructure to apply under this FOA.

NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdoctoral Fellows (F32 Clinical Trial Not Allowed)

Thu, 2024-11-07 01:15
Funding Opportunity PAR-25-234 from the NIH Guide for Grants and Contracts. The purpose of this award is to support outstanding scientific training of highly promising postdoctoral candidates with outstanding mentors. Candidates are eligible to apply for support from this program from ~12 months prior to the start of the proposed postdoctoral position to within 12 months after starting in postdoctoral position. Based on the early timeframe of eligibility, and the discouragement of inclusion of preliminary data, this NINDS F32 seeks to foster early, goal-directed planning and to encourage applications for bold and/or innovative projects by the candidate that have the potential for significant impact. Applications are expected to incorporate strong training in quantitative reasoning and the quantitative principles of experimental design and analysis. Support by this program is limited to the first 3 years of a candidate's activity in a specific laboratory or research environment, so as to further encourage early fellowship application and timely completion of mentored training of the postdoctoral candidate in a single environment.

Engaging Loved ones in Recovery Processes to Enhance Recovery Capital and Outcomes (R61/R33 Clinical Trial Optional)

Wed, 2024-11-06 11:17
Funding Opportunity RFA-DA-26-024 from the NIH Guide for Grants and Contracts. Outside of research with adolescents, there is a relative dearth of research on how to effectively leverage and support relationships between people with addiction and their loved ones to improve treatment navigation, engagement and recovery outcomes. As a result, this NOFOs purpose is to address this crucial research gap by supporting studies to improve engagement of support persons. This initiative would support pragmatic trials focused on scalable, sustainable adaptations to existing EBPs and service delivery frameworks that emphasize enhancing engagement of loved ones and support persons, thereby strengthening recovery capital and increasing the likelihood of stable recovery. Approaches of interest include testing adaptations or new interventions that: 1) reduce stigma toward addiction and MOUD among support persons; 2) provide assistance to support persons in navigating care options for their loved one; 3) formally engage support persons in services; 4) leverage support persons as lay interventionists; and 5) enhance well-being and coping skills among support persons.

Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)

Wed, 2024-11-06 11:06
Funding Opportunity PAR-24-306 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research. With this NOFO, the NCI intends to encourage submission of projects devoted to demonstrating that mammalian models or their derivatives used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patients' benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that employ mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this FOA could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally

Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)

Wed, 2024-11-06 10:16
Funding Opportunity PAR-25-175 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.

Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)

Wed, 2024-11-06 10:11
Funding Opportunity PAR-24-311 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to invite research grant applications (R01) for the development and use of current and emerging molecular imaging methods to gain fundamental insights into cancer inflammation in vivo. The motivation for this initiative is that much of current imaging research into the role of inflammation in cancer is largely based on in vitro and ex vivo methods with limited utilization of imaging approaches that could lead to significant new insights relevant to dynamic cancer and inflammation interactions. Utilization of molecular imaging probes in pre-clinical and clinical investigations for precise temporal resolution at the molecular and cellular level are valuable approaches for identification and characterization of in vivo inflammatory cellular physiology in cancers and of molecular changes in response to treatment. This FOA encourages applications that focus on developing integrated imaging approaches to interrogate the role of inflammation in cancer through strong cross-field collaboration between cancer basic science researchers and imaging scientists. These collaborations are expected to advance science and understanding of cancer inflammation interactions.

NIA Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required)

Wed, 2024-11-06 09:40
Funding Opportunity PAR-25-222 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites applications for implementation of investigator-initiated multi-site interventional clinical trials (all phases). The trials should be hypothesis-driven, milestone-defined, and related to NIA's research mission. Information about NIA's mission can be found on the NIA website.

NIA Academic Leadership Career Award (K07 Independent Clinical Trial Not Allowed)

Wed, 2024-11-06 09:28
Funding Opportunity PAR-24-321 from the NIH Guide for Grants and Contracts. The objective of the NIA Academic Leadership Career Award (K07) is to provide support for established investigators who have the expertise and leadership skills to enhance aging and/or Alzheimer's Disease (AD) and Alzheimers Disease Related Dementias (ADRD)research capacity within their academic institution. Through this award, investigators will endeavor to develop research and educational infrastructure, mentorship, and career development activities in support of new or emerging areas of aging and/or AD/ADRDresearch. These may include, but are not limited to, courses, curricula, research support, pilot funding, travel awards, visiting scholars, or networks. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by another investigator.

Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional)

Wed, 2024-11-06 07:20
Funding Opportunity PAR-25-221 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) aims to support research on interdisciplinary population approaches to increasing awareness of the relationship between alcohol and cancer risk, understanding and changing social norms related to alcohol consumption, developing and/or evaluating alcohol policy approaches, and the development, testing, and implementation of population-level interventions to reduce alcohol-related cancer risk. Applications that address multiple levels of consumption, such as moderate and heavy drinking, are of particular interest, as well as those focusing on alcohol use disorder (AUD) from the perspective of cancer prevention and control. Proposals addressing understudied areas are encouraged, as is attention to underrepresented minority (URM) populations experiencing cancer and alcohol-related disparities such as American Indian, Alaskan Native, and sexual and gender minority populations.

Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)

Wed, 2024-11-06 07:15
Funding Opportunity PAR-25-079 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate translation of scientific discoveries and engineering developments in imaging, data science and/or spectroscopic technologies into methods or tools that address contemporary problems in understanding the fundamental biology, potential risk of development, diagnosis, treatment, and/or disease status for cancer or other disease.

Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)

Wed, 2024-11-06 04:48
Funding Opportunity PAR-25-063 from the NIH Guide for Grants and Contracts. The objective of this Notice of Funding Opportunity (NOFO) is to stimulate research in 1) discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to psychiatric disorders; and 2) to generate new insight into the biology of relevant diseases and processes that have yet to be validated as important drug targets.

Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)

Wed, 2024-11-06 04:24
Funding Opportunity PAR-24-325 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications from research partnerships formed by academic and industrial investigators to accelerate the development and adoption of promising bioengineering tools and technologies that can address important biomedical problems. The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine. Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies. The goal of the program is to support technological innovations that deliver new capabilities which can realize meaningful solutions within 5 10 years.

Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)

Wed, 2024-11-06 04:15
Funding Opportunity PAR-25-198 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states.

Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)

Wed, 2024-11-06 04:15
Funding Opportunity PAR-25-199 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states.

Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)

Wed, 2024-11-06 02:25
Funding Opportunity PAS-25-205 from the NIH Guide for Grants and Contracts. The Stimulating Hematology Investigation: New Endeavors (SHINE) program is intended to promote innovative, high-quality nonmalignant hematology research relevant to the missions of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Aging (NIA), and the National Heart, Lung, and Blood Institute (NHLBI). Investigator-initiated research project grant applications (R01s) in specific areas of basic and early translational hematology research are invited to this program that supports growth in the nonmalignant hematology research domain. Specific emerging topics that are at the leading edge of the field will change over time and will be updated annually through the NIH Guide to Grants and Contracts and hyperlinked to this NOFO.

Pages